Lonza, Vertex to build a new cell therapy manufacturing facility for the biotech’s type 1 diabetes therapies

Tyler Patchen

News Reporter

The Swiss contract manufacturer Lonza and Vertex plan to build a facility designed to manufacture the biotech’s type 1 diabetes cell therapies in a deal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lonza, Vertex to build a new cell therapy manufacturing facility for the biotech’s type 1 diabetes therapies

Tyler Patchen

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

Roivant makes another deal, selling Dermavant to Organon for up to $1.2B

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

Breaking down silos with a new quantitative approach to drug development

Lon­za, Ver­tex to build a new cell ther­a­py man­u­fac­tur­ing fa­cil­i­ty for the biotech’s type 1 di­a­betes ther­a­pies

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Lonza, Vertex to build a new cell therapy manufacturing facility for the biotech’s type 1 diabetes therapies